Table 2.

Effect of previous fracture and antiresorptive use on fractures following initiation of teriparatide on patients that were persistent and nonpersistent with teriparatide

	Fracture patients		Non-fracture patients		p value	Overall
	N = 1527		N = 9880			N = 11,407
	N value	Percent	N value	Percent		N value	Percent
Persistent with teriparatide	623	40.8	4835	48.9	<0.001	5458	47.8
Patients with baseline fracture	234	37.6	1132	23.4	<0.001	1366	25.0
And with baseline antiresorptive use	174	27.9	777	16.1	<0.001	951	17.4
And without baseline antiresorptive use	60	9.6	355	7.3	0.514	415	7.6
Patients without baseline fracture	389	62.4	3703	76.6	<0.001	4092	75.0
And with baseline antiresorptive use	264	42.4	2534	52.4	<0.001	2798	51.3
And without baseline antiresorptive use	125	20.1	1169	24.2	<0.001	1294	23.7
Nonpersistent with teriparatide	904	59.2	5045	51.1	<0.001	5949	52.2
Patients with baseline fracture	310	34.3	1244	24.7	<0.001	1554	26.1
And with baseline antiresorptive use	194	21.5	787	15.6	<0.001	981	16.5
And without baseline antiresorptive use	116	12.8	457	9.1	<0.001	573	9.6
Patients without baseline fracture	594	65.7	3801	75.3	0.749	4395	73.9
And with baseline antiresorptive use	371	41.0	2204	43.7	0.084	2575	43.3
And without baseline antiresorptive use	223	24.7	1597	31.7	0.121	1820	30.6
Total	1527	100.0	9880	100.0		11,407	100.0
Patients with baseline fracture	544	35.6	2376	24.0	<0.001	2920	25.6
And with baseline antiresorptive use	368	24.1	1564	15.8	<0.001	1932	16.9
And without baseline antiresorptive use	176	11.5	812	8.2	<0.001	988	8.7
Patients without baseline fracture	983	64.4	7504	76.0	<0.001	8487	74.4
And with baseline antiresorptive use	635	41.6	4738	48.0	<0.001	5373	47.1
And without baseline antiresorptive use	348	22.8	2766	28.0	<0.001	3114	27.3

The italicized values denote p < 0.001